

1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifiers

Product name : Erdafitinib

Product Number : 10-4999

Brand : Focus Biomolecules

CAS-No. : 1346242-81-6

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : For Laboratory Research Use Only

1.3 Details of the supplier of the safety data sheet

Company : Focus Biomolecules
400 Davis Drive, Suite 600
Plymouth Meeting, PA 19462

Telephone : +1 855362-8721

E-mail : support@focusbiomolecules.com

1.4 Emergency telephone number

Emergency Phone # : CHEMTREC within USA/Canada 1-800- 424-9300
CHEMTREC outside USA/Canada 1-703-527-3887

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)

Skin irritation (Category 1), H317

Serious irritation (Category 2A), H319

Reproductive toxicity (Category 2), H361

Specific target organ toxicity - repeated exposure oral (Category 1)

For the full text of the H-Statements mentioned in this Section, see Section 16.

GHS Label elements, including precautionary statements

Pictogram

2.2



Signal word Hazard
statement(s)

Danger

H317 May cause an allergic skin reaction.

H319 Causes serious eye irritation.

H361 Suspected of damaging fertility or the unborn child.

H372 Causes damage to organs through prolonged or repeated exposure if swallowed

Precautionary statement(s)	
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P260	Do not breathe dust
P264	Wash skin thoroughly after handling.
P270	Do not eat, drink, or smoke when using this product
P272	Contaminated work clothing should not be allowed out of the workplace.
P280	Wear protective gloves/ eye protection/ face protection.
P302 + P352	IF ON SKIN: Wash with plenty of soap and water.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P333 + P313	If skin irritation or rash occurs: Get medical advice/ attention.
P337 + P313	If eye irritation persists: Get medical advice/ attention.
P463	Wash contaminated clothing before reuse.
P405	Store locked up.
P501	Dispose of contents/ container to an approved waste disposal plant.

2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Formula	: C ₂₅ H ₃₀ N ₆ O ₂
Molecular Weight	: 446.56 g/mol
CAS-No.	: 1346242-81-6

Hazardous components

Component	Classification	Concentration
Erdafitinib		
	Skin Irrit. 1; Eye Dam. 2A; Repr. 2; STOT CE 1; H317, H319, H361, H372	-

For the full text of the H-Statements mentioned in this Section, see Section 16.

4. FIRST AID MEASURES

4.1 Description of first aid measures

General advice

Consult a physician. Show this safety data sheet to the doctor in attendance. Move out of dangerous area.

If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

In case of skin contact

Wash off with soap and plenty of water. Consult a physician.

In case of eye contact

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3 Indication of any immediate medical attention and special treatment needed

no data available

5. FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture

Carbon oxides, nitrogen oxides (NO_x)

5.3 Advice for firefighters

Wear self contained breathing apparatus for fire fighting if necessary.

5.4 Further information

no data available

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Avoid dust formation. Avoid breathing dust. Ensure adequate ventilation.

Evacuate personnel to safe areas. Avoid breathing dust.

For personal protection see section 8.

6.2 Environmental precautions

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4 Reference to other sections

For disposal see section 13.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols.

Provide appropriate exhaust ventilation at places where dust is formed.

For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

Recommended storage temperature: -20 °C

7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components with workplace control parameters

TWA: 0.0051 mg/m³; STV: 0.010 mg/100cm³; PBOEL-HHC: 3 A.

8.2 Exposure controls

Appropriate engineering controls

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

Personal protective equipment

Eye/face protection

Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Full contact

Material: Nitrile rubber

Minimum layer thickness: 0.11 mm

Break through time: 480 min

Material tested: Dermatril® (KCL 740 / Aldrich Z677272, Size M)

Splash contact

Material: Nitrile rubber

Minimum layer thickness: 0.11 mm

Break through time: 480 min

Material tested: Dermatril® (KCL 740 / Aldrich Z677272, Size M)

data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374

If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It should not be construed as offering an approval for any specific use scenario.

Body Protection

Complete suit protecting against chemicals, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Respiratory protection

Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Control of environmental exposure

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

- | | |
|---|-------------------|
| a) Appearance | Form: solid |
| b) Odour | no data available |
| c) Odour Threshold | no data available |
| d) pH | no data available |
| e) Melting point/freezing point | no data available |
| f) Initial boiling point and boiling range | no data available |
| g) Flash point | no data available |
| h) Evaporation rate | no data available |
| i) Flammability (solid, gas) | no data available |
| j) Upper/lower flammability or explosive limits | no data available |

k)	Vapour pressure	no data available
l)	Vapour density	no data available
m)	Relative density	no data available
n)	Water solubility	insoluble
o)	Partition coefficient: n-octanol/water	no data available
p)	Auto-ignition temperature	no data available
q)	Decomposition temperature	no data available
r)	Viscosity	no data available
s)	Explosive properties	no data available
t)	Oxidizing properties	no data available

9.2 Other safety information

no data available

10. STABILITY AND REACTIVITY

10.1 Reactivity

no data available

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

no data available

10.4 Conditions to avoid

no data available

10.5 Incompatible materials

Oxidizing agents

10.6 Hazardous decomposition products

Other decomposition products - no data available

In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity

Oral: LD50 (Rat, male): >1000mg/kg

LD50 (Dog): >45 mg/kg

Inhalation: no data available

Dermal: No data available

no data available

Skin corrosion/irritation

Product is a skin sensitizer

Serious eye damage/eye irritation

Corrosive to eyes

Respiratory or skin sensitisation

Germ cell mutagenicity

Bacterial Reverse Mutation Test: Negative

Carcinogenicity

- IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
- ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.
- NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.
- OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

Reproductive toxicity

Reproductive toxicity:

May result in reproductive system adverse effects based on therapeutic class.

Reproductive toxicity - rat - Intravenous

Species: Rat, female Application Route: Oral Dose: 0, 1, 4, 8 mg/kg body weight General Toxicity Maternal: NOAEL: 4 mg/kg body weight Teratogenicity: NOAEL: 1 mg/kg body weight Developmental Toxicity: NOAEL: 1 mg/kg body weight Embryo-foetal toxicity: NOAEL: 1 mg/kg body weight Method: OECD Test Guideline 414 GLP: yes

Specific target organ toxicity - single exposure

No data available

Specific target organ toxicity - repeated exposure

Oral Target Organs : cartilage, eye - retina, vascular system, Mammary gland, lacrimal gland, glandular stomach
Assessment : Causes damage to organs through prolonged or repeated exposure.

Aspiration hazard

no data available

Additional Information

RTECS: N/A

12. ECOLOGICAL INFORMATION

12.1 Toxicity

no data available

12.2 Persistence and degradability

no data available

12.3 Bioaccumulative potential

no data available

12.4 Mobility in soil

no data available

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6 Other adverse effects

no data available

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product

Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.

Contaminated packaging

Dispose of as unused product.

14. TRANSPORT INFORMATION

DOT (US)

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

15. REGULATORY INFORMATION

SARA 302 Components

SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components

	CAS-No.	Revision Date
Erdafitinib	1346242-81-6	

New Jersey Right To Know Components

	CAS-No.	Revision Date
Erdafitinib	1346242-81-6	

California Prop. 65 Components

	CAS-No.	Revision Date
Erdafitinib	1346242-81-6	

16. OTHER INFORMATION

Full text of H-Statements referred to under sections 2 and 3.

H317	Serious eye damage
H319	Causes skin irritation.
	May cause an allergic skin reaction.

H361	Suspected of damaging fertility or the unborn child.
H372	Causes damage to organs (cartilage, eye - retina, vascular system, Mammary gland, lacrimal gland, glandular stomach) through prolonged or repeated exposure if swallowed.

Copyright 2026 Focus Biomolecules. License granted to make unlimited paper copies for internal use only. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. Materials are intended for Laboratory Use only and must be used by qualified technicians. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Focus Biomolecules and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product.

Version: 1.0

Revision Date: 02/20/2026